<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Liu M</submitter><funding>China Scholarship Council</funding><funding>Nutricia Research B.V., Utrecht, the Netherlands</funding><funding>China Scholarship Council (CSC)</funding><pagination>137-148</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9291823</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>52(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Two to four percentage of infants are affected by cow's milk allergy (CMA), which persists in 20% of cases. Intervention approaches using early oral exposure to cow's milk protein or hydrolysed cow's milk formula are being studied for CMA prevention. Yet, concerns regarding safety and/or efficacy remain to be tackled in particular for high-risk non-exclusively breastfed infants. Therefore, safe and effective strategies to improve early life oral tolerance induction may be considered.&lt;h4>Objective&lt;/h4>We aim to investigate the efficacy of CMA prevention using oral pre-exposure of two selected 18-AA β-lactoglobulin-derived peptides loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) in a whey-protein induced CMA murine model.&lt;h4>Methods&lt;/h4>The peptides were l</pubmed_abstract><journal>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</journal><pubmed_title>Inhibition of cow's milk allergy development in mice by oral delivery of β-lactoglobulin-derived peptides loaded PLGA nanoparticles is associated with systemic whey-specific immune silencing.</pubmed_title><pmcid>PMC9291823</pmcid><funding_grant_id>201707720004</funding_grant_id><pubmed_authors>Liu M</pubmed_authors><pubmed_authors>van Nostrum CF</pubmed_authors><pubmed_authors>Thijssen S</pubmed_authors><pubmed_authors>Hennink WE</pubmed_authors><pubmed_authors>Willemsen LEM</pubmed_authors><pubmed_authors>Garssen J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Inhibition of cow's milk allergy development in mice by oral delivery of β-lactoglobulin-derived peptides loaded PLGA nanoparticles is associated with systemic whey-specific immune silencing.</name><description>&lt;h4>Background&lt;/h4>Two to four percentage of infants are affected by cow's milk allergy (CMA), which persists in 20% of cases. Intervention approaches using early oral exposure to cow's milk protein or hydrolysed cow's milk formula are being studied for CMA prevention. Yet, concerns regarding safety and/or efficacy remain to be tackled in particular for high-risk non-exclusively breastfed infants. Therefore, safe and effective strategies to improve early life oral tolerance induction may be considered.&lt;h4>Objective&lt;/h4>We aim to investigate the efficacy of CMA prevention using oral pre-exposure of two selected 18-AA β-lactoglobulin-derived peptides loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) in a whey-protein induced CMA murine model.&lt;h4>Methods&lt;/h4>The peptides were l</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jan</publication><modification>2025-04-05T11:50:38.613Z</modification><creation>2022-08-06T14:48:04.088Z</creation></dates><accession>S-EPMC9291823</accession><cross_references><pubmed>34145667</pubmed><doi>10.1111/cea.13967</doi></cross_references></HashMap>